The miniature models have the potential to significantly speed up vaccine development, advance cancer treatment research, and enhance health outcomes for a wide range of diseases. To gain deeper ...

AAV production results in a mix of capsids ... and amplify biological materials such as antibodies, proteins, nucleic acids, ...

Our synthetic hydrogels create a breakthrough environment for human immune organoids, allowing us to model antibody production from scratch ... mark a shift toward in vitro models that more closely ...

These miniature immune system models -- known as human immune organoids -- mimic the real-life environment where immune cells learn to recognize and attack harmful invaders and respond to vaccines.

SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance ...

Our platforms also enable efficient production of complex antigens and antibodies, essential for developing vaccines ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

RNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than ...

And these data continue to demonstrate broad cross-neutralizing antibody responses to each new strain ... And we believe ...

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...